Compare JBHT & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBHT | WST |
|---|---|---|
| Founded | 1961 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.2B | 18.5B |
| IPO Year | 1994 | 2004 |
| Metric | JBHT | WST |
|---|---|---|
| Price | $282.74 | $316.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 7 |
| Target Price | $220.80 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 809.8K | 678.7K |
| Earning Date | 04-15-2026 | 04-23-2026 |
| Dividend Yield | ★ 0.73% | 0.30% |
| EPS Growth | ★ 10.07 | 1.49 |
| EPS | 1.49 | ★ 1.92 |
| Revenue | ★ $7,189,568,000.00 | $2,886,900,000.00 |
| Revenue This Year | $5.76 | $6.76 |
| Revenue Next Year | $6.62 | $6.22 |
| P/E Ratio | $187.95 | ★ $164.74 |
| Revenue Growth | ★ 9.67 | 1.95 |
| 52 Week Low | $130.13 | $206.80 |
| 52 Week High | $281.62 | $330.88 |
| Indicator | JBHT | WST |
|---|---|---|
| Relative Strength Index (RSI) | 70.68 | 58.50 |
| Support Level | $195.69 | $295.90 |
| Resistance Level | N/A | $321.34 |
| Average True Range (ATR) | 7.20 | 8.16 |
| MACD | 1.44 | -1.33 |
| Stochastic Oscillator | 96.56 | 68.94 |
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (48% of sales), dedicated trucking services that provide customer-specific fleet needs (27%), for-hire truckload (6%), heavy goods final-mile delivery (7%), and asset-light truck brokerage (12%).
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.